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ABSTRACT
Silicon containing pyridine and quinoline sulfides have been prepared using phase transfer catalytic
system thiol/alkyl halide / solid KOH/18-crown-6 toluene. The target S-ethers were isolated in yields up to
81%. The cytotoxicity of the synthesized compounds was studied. Among pyridine sulfides S-[3-(1-methyl-
1-silacyclohexyl)propyl] derivatives 5e and 6e exhibit the highest cytotoxicity. Aliphatic silicon derivatives
were considerably less active. 8-[(Trimethylsilylmethyl)thio]quinoline (8a) exhibits the highest activity
among quinoline sulfides.
INTRODUCTION
Pyridine and quinoline sulfides and related compounds exhibit a wide range of biological activity/1/o
Among these activities antitumor and cytotoxic activities of pyridine /2-8/ and quinoline /9-12/ sulfides were
described.
The known methods for the preparation of sulfides are based on reaction of hetaryl thiols with alkyl or
aryl halides in the presence of K2CO3 Me2Co/13/, NaOMe DMF/14/or Nail MezSO4 /15/ systems.
Recently we described two simple phase transfer catalytic (PTC) methods for the preparation of hetaryl
sulfides in the hetaryl thiol alkyl halide solid K2CO3 18-crown-6 toluene/1/or hetaryl S-acetate alkyl
halide solid KOH 18-crown-6 benzene systems/16/.
We have found that 3-(hataryltio)-l-propynyl(trimethyl)silanes exhibit high cytotoxicity /17/. In the
present work the novel N-beterocyclic sulfides with trialkylsily and silacyclic substituents have been
synthesized as potential antitumor agents.
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MATERIALS AND METHODS
Chemistry
H NMR spectra were recorded on a Varian 200 Mercury instrument using CDCIa as a solvent and
hexamethyldisiloxane (HMDSO) as an internal standard (0.055 ppm). Mass spectra were registered on a GC-
MS HP 6890 (70 eV). GC analysis was performed on a Chrom-5 instrument equipped with flame-ionization
detector using glass column packed with 5% OV-101 / Chromosorb W-HP (80-100 mesh) (1.2 rn x 3 mm).
Bromomethyltrimethylsilane, 3-iodopropyltrimethylsilane, 1-(3-iodopropyl)-l-methylsilaeyclopentane and 1-
(-iodopropyl)-l-methylsilaeyclohexane were obtained by Grignard reaction /18,19/ from corresponding
ehloropropylmethyldichlorosilane with the following exchange of chlorine atom by iodine using
NaI/(CH3)2CO in excellent yields.
Generalprocedurefor alkylation ofthiols 1-4.
Finely powdered dry K2CO3 (0.82 g, 6 mmol) was added to a suspension of thiol 1-4 (compound 4 was
used as potassium salt) (2 mmol), silane (2 mmol) and 18-crown-6 (0.053 g, 0.2 mmol) in 1.5 ml of toluene.
The mixture was refluxed with stirring to achieve the disappearance of the substrates, filtered over the thin
silica gel layer and concentrated under reduced pressure. The residue was purified by column chromato-
graphy on silicagel (eluent benzene ethyl acetate in different mixtures) to give products 5-8. The results are
shown in Tables 3.
In vitro cycotoxicity assay
Monolayer cell lines were cultivated for 72 h in DMEM standard medium without an indicator and
antibiotics. After the ampoule was defrozen not more than four passages were performed. The control cells
and cells with tested substances in the range of 2-5 104 cell/mL concentration (depending on line nature)
were placed on separate 96 wells plates. Solutions containing test compounds were diluted and added in
wells to give the final concentrations of 50, 25, 12.5, and 6.25 tg/mL. Control cells were treated in the same
manner only in the absence of test compounds. Plates were cultivated for 72 h. The quantity of survived cells
was determined using crystal violet (CV) or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide
(MTT) coloration that was assayed by multiscan spectrophotometer. The quantity of alive cells on the control
plate was taken in calculations as 100%/20,21/. The concentration ofNO was determined according to/20/.
RESULTS AND DISCUSSION
Chemistry
Alkylation of pyridine and quinoline thiols 1-4 has been carried out in the phase transfer catalytic system
silyl alkyl halide solid K2CO3/18-crown-6 toluene at reflux. Sulfides 5-8 were isolated in 20-81% yield by
column chromatography (Table 1).
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The spectroscopic data of compounds 5e, 6b, 6e, 6e, 7b, 7e, 7e are presented in Tables 2, 3. Compounds
5b, 5e, 8a, 8d, 8e were described in/1/.
Thiol
TABLE 1
Synthesis of silyl derivatives ofhetaryl thiols
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TABLE 2
H NMR data ofpyridine and quinoline sulfides
Compound
6b
71}
5 (ppm, CDCI / HMDSO)
-0.01(s, 6H, SiCH), 0.51 (m, 2H, SiCHj(CH)sCH), 0.68 (m,2H, SiCH), 0.8-1.7
(m, 15H, CHCH_CH and CH_(CH_)sCH), 3.18 (t, 2H, J = 7.4 Hz, CCH), 6.98
_.(m, 1 H, 5-H), 7.17 (m, 1 H, 3-H), 7.44(m, 1 H, 4-H).,. 8.45. (m, 1 H, 6-H)
0.00 (s, 9H, Si(CH)), 0.66 (m, 2H, CHSi), 1.70 (m, 2H, CH2CH_.2CHSi), 2.97 (t,
2H, J= 7.2 Hz, S.CH), 7.09 (m, 1 H, 3H and 5-H),....8.37..........(m, 1H, 2-H and 6-H),
-0.03(s, 6H, SiCH), 0149 (m, 2H, SiCH_(CH)sCH), 0.66 (m,2H, SiCH), 0.8-1.7
(m, 15H, CHCH_.CH_ and CH(CH_)sCH), 2.97 (t, 2H, J = 7.4 Hz, CCH), 7.09
.(m, 2H, 3-H and 5-H), 8.37 (m, 2H, 2-H and 6-H)
0.05 (s, 3H, SiCH), 0.60 (m, 6H, SiCH), 1.63 (m, 8H, CH2(CHj)CH2 in silacycle
and CH2CH_.2CH2Si), 2.97 (t, 2H, J= 7.4 Hz, SCH2), 7.09 (m, 2H, 3-H and 5-H),
8.37 (m, 2H, 2-H and 6-H)
0.02 (s, 9H, Si(CH)), 0.76 (m, 2H, CH_Si), 1.80 (m, 2H, CH2CH_.2CH2Si), 3.34 (t,
2H, J= 7.4 Hz, SCH), 7.22, 7.44, 7.67 and 7.90 (all m, 6H, quinoline ring protons)
-0.02(s, 6H, SiCH), 0.51 (m, 2H, SiCH_.2(CH)sCH), 0.72 (m,2H, SiCH2), 0.9-1.8
(m, 15H, CH2CH_.CH_ and CH(CH_)sCH_.), 3.34 (t, 2H, J = 7.4 Hz, CCH2), 7.23,
7.40, 7.68 and 7.90 (all m, 6H, q.uinoline ring protons)
0.05 (s, 3H, SiCH), 0.57 and 0.67 (both m, 6H, SiCH2), 1.64 (m, 8H,
CH2(CH_.2)CH2 in silacycle and CH2CH_2CH2Si), 3.36(t, 2H, J= 7.0 Hz, SCH2), 7.43,
7.69, 7.90 and 8.00 .(all m, 6H, quinoline ring protons)
TABLE 3
Mass-spectroscopic data of pyridine and quinoline sulfides
5c 1294 (M’- Me, 10), 262 (5), 210 (100), 168 (52), 154 (7), 138 (13), 111 (53), 78
6b 1225 (M’, 5), 210 (97), 183 (9), 168 (57), 151 (7), 73 (100), 59 (14), 51 (15), 45 < 1), 294 (5), 210 (100), 168 (42), 154 (7), 138 (4), 73 (5), 59 (31), 43
26), 222 (100), 209 (12), 195 (12), 180 (41), 166 (28), 152 (15), 138
7(:
1275 (M, 3), 260 (8), 228 (8), 218 (18), 188 (15), 175 (21), 161 (100), 128 (38),
1360 (M, 1),_344(4), 312 (5), 260 (37), 218 (33), 188 (11), 175 (1, 161 (-
1315 (22), 272(83),_244 (28)! 231 (38), 217 (33), 188 (18), 174 (1; 61 (-0-
143 13,128 67,101 14,85 32,59 21:
In vitro cytotoxicity
Cytotoxic activity of synthesized silicon-containing sulfides 5-8 was tested in vitro on two monolayer
tumor cell lines: MG-22A (mouse hepatoma) and HT-1080 (human fibrosarcoma). Concentrations providing
50% oftumor death effect were determined according to the known procedure/22/using 96 well plates.
The experimental evaluations of cytotoxic properties are presented in Table 4. A preliminary analysis of
the structure-activity relationship for the cytotoxic action clearly indicates the strong influence of the
silylalkyl substituent structure.
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TABLE 4
In vitro cell cytotoxicity and the ability of intracellularNO generation
caused by silicon and containing pyridine and quinoline sulfides
No Compound HT- 1080
TDo
5b 4 400 4
SSiM%
5c 78 44 39
N,..
S.StMe
6b 67 167 1.2
6c 52 114
7b "_T "] 73 250 3.8
S,SiMe
7c IL >100 33
8a 2.5 350 3.5
MezSiS
8d """"N 17 300 22
SS=
8e 21.5 350 8.5
S.
Concentration (lag/mL) providing 50% cell killing effect [(CV+MTT)/2)
NO concentration (%) (CV: coloration).
MG- 22A
NOI.%’C.V.. TDo" NO, %CV’’
15.5
>100
300
650
400
250
275
450
200
36
157
200
200
400
49lld. , Nos. I-2, 2002 Synthesis and Cytotoxicity ofSilicon Containing Pyridine
and Quinoline Sulfides
Pyridine and quinoline sulfides bearing dimethylheptylsilyl group at the sulfur atom (5c, 6c, and 7c) have
a slight eytotoxic effect (> 15.5 g/mL). The substitution of dimethylheptylsilyl group by trimethylsilyl (Sb,
6b, and 7b) or silahexyl group (Se, 6e, and 7e) results in considerable increase of the eytotoxic activity. It
must be noted that the activity of studied compounds depends on the tumor type. In general, all silicon
containing sulfides (5-8) show the expressed selectivity on mouse hepatoma MG 22A cell line. However,
8-trimethylsilylmethylmereaptoquinoline 8a exhibits a greater toxicity on HT 1080 cells (2.5 tg/mL)
contrary to MG 22A (3.5 tg/mL). Comparison of the tumor growth inhibition for derivatives 5- 7b and 5
7 c shows a higher eytotoxie activity of the trimethylsilylpropyl group containing sulfides with respect to
dimethylheptylsilylpropyl substituted sulfides. Among pyridine derivatives 4-[3-(l-methyl-1-
silacyclohexyl)propyl]pyridine sulfide 6e exhibits the highest eytotoxicity on MG 22A (<1 g/mL). The
most active in the series of quinoline sulfides is 8-[(trimethylsilylmethyl)thio]quinoline 8a (2.5 tg/mL on
human fibrosarcoma HT- 1080 cell line). Studied pyridine and quinoline derivatives have a medium NO-
induction ability, 2-(3’-dimethylheptylsilylpropyl)pyridine sulfide 5c being the most active (650% on MG-
22A test).
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